ARS Investment Partners LLC Has $8.54 Million Stake in Novo Nordisk A/S $NVO

ARS Investment Partners LLC grew its stake in Novo Nordisk A/S (NYSE:NVO) by 69.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 153,916 shares of the company’s stock after acquiring an additional 63,155 shares during the period. ARS Investment Partners LLC’s holdings in Novo Nordisk A/S were worth $8,541,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of NVO. NewSquare Capital LLC grew its stake in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the period. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Novo Nordisk A/S in the second quarter worth $37,000. State of Wyoming acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $38,000. Maseco LLP bought a new position in Novo Nordisk A/S in the second quarter valued at approximately $39,000. Finally, Copeland Capital Management LLC grew its position in shares of Novo Nordisk A/S by 47.3% in the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after acquiring an additional 186 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 1.9%

Shares of NVO stock opened at $52.61 on Thursday. The stock has a market cap of $234.90 billion, a P/E ratio of 15.29 and a beta of 0.67. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The stock has a 50 day simple moving average of $49.47 and a 200 day simple moving average of $57.12.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. On average, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on NVO shares. Morgan Stanley reaffirmed an “underweight” rating and set a $42.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a report on Tuesday. The Goldman Sachs Group lowered their price target on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, November 28th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $53.33.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approval of the oral Wegovy pill gives Novo a first‑to‑market position in oral GLP‑1 obesity treatments, expanding addressable market and making the drug easier to prescribe/scale than injectables. Explainer: What Novo Nordisk’s weight-loss pill approval means
• Positive Sentiment: Novo plans a U.S. launch in early January and is targeting the cash‑pay market at an introductory price (~$149/month reported), which could accelerate uptake and revenue if demand matches expectations. Wegovy pill to test demand from consumers with cash
• Positive Sentiment: Market reaction: multiple outlets report a sharp pre‑market/early session rally and unusually large call‑option activity, signaling investor optimism and short‑term speculative interest. Shares pop after GLP-1 pill approval
• Neutral Sentiment: Analysts highlight that NVO trades at a depressed forward multiple (seekingalpha note), so the approval could meaningfully re‑rate the stock if commercial execution succeeds — but valuation upside depends on sustained share gains. Seeking Alpha: The real comeback starts now with the Wegovy pill
• Negative Sentiment: Competition and pricing pressure remain material risks — Eli Lilly is close behind with its own oral option and dominates prescriptions with injectables, so market share battles and price competition could limit upside. Lilly, Novo lock horns in India’s obesity drug race
• Negative Sentiment: Geographic/generic risks—lower‑cost generics and delayed filings in some markets (e.g., Canada/India) could pressure future volumes and margins in regional markets. Canadians face longer wait for copycat Ozempic

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.